Involving Family and Social Support Systems in Tobacco Cessation Treatment for Patients With Cancer
Search for other papers by The Cancer Center Cessation Initiative Family and Social Support Systems Working Group in
Current site
Google Scholar
PubMed
Individuals from the family and social support network of patients with cancer can have a pivotal role in reinforcing patients’ efforts to become and remain tobacco-free. This support is critical along the entire continuum of cancer care. Although NCI-designated Cancer Centers across the United States are increasingly offering tobacco cessation services as a result of the NCI Cancer Center Cessation Initiative (C3I), engaging patients’ family and other support network in tobacco treatment is not yet a routine practice. To facilitate the consideration and involvement of patients’ social support systems (including family, peers, and non–healthcare provider caregivers), we formed the C3I Family and Social Support Systems Working Group. This paper describes the current practices and challenges among C3I cancer centers centers in engaging the support systems of patients with cancer in order to reduce tobacco use and/or secondhand smoke exposure. Building on this knowledge, this Working Group proposes a research agenda to facilitate support persons’ involvement in tobacco treatment as part of oncology care. The research priorities identified include establishing (1) evidence-based strategies for engaging family and social support systems in patients’ cessation efforts, (2) interventions to provide cessation treatment options to support persons, and (3) best practices to routinely identify and engage family and social support systems in patients’ cessation efforts.
The Cancer Center Cessation Initiative Family and Social Support Systems Working Group
Tracy E. Crane PhD, RDN1, Janice Y. Tsoh PhD2, Sarah D. Hohl PhD, MPH3, Adam O. Goldstein MD, MPH4, Katie L. Lenhoff MPH5, Jamie Ostroff PhD6, Kimberly Shoenbill MD, PhD4, Kendall Fugate-Laus BS7, Elyse R. Park PhD, MPH8, Jennifer Peregoy NCTTP9, Graham W. Warren MD, PhD10, Robert Adsit MEd11, Mara Minion MA3, Danielle Pauk BS3, and Betsy Rolland PhD, MLIS, MPH3,12
1 Biobehavioral Health Sciences Division, College of Nursing, The University of Arizona, Tucson, Arizona; | 2 Department of Psychiatry and Behavioral Sciences, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; | 3 Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin; | 4 Department of Family Medicine, University of North Carolina, Chapel Hill, North Carolina; | 5 Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Dartmouth, New Hampshire; | 6 Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York; | 7 Department of Psychology, Virginia Commonwealth University, Richmond, Virginia; | 8 Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts; | 9 Cancer Center, University of Virginia, Charlottesville, Virginia; | 10 Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina; | 11 Department of Medicine, Center for Tobacco Research and Intervention, School of Medicine and Public Health, University of Wisconsin-Madison; and | 12 Institute for Clinical and Translational Research, University of Wisconsin-Madison, Madison, Wisconsin.
Submitted July 26, 2021; final revision received September 14, 2021; accepted for publication September 16, 2021.
Disclosures: G.W. Warren has disclosed participating in research for the Agency for Healthcare Research and Quality and serving as a consultant for the Canadian Partnership Against Cancer. The remaining individuals have disclosed no relevant financial relationships.
Funding: This supplement was funded by the C3I Coordinating Center contract from the National Cancer Institute (CRDF Award #66590). In addition, authors received funding for their C3I participation via a supplement to their NCI P30 cancer center support grant during the period 2017–2021.
© 2019-2024 National Comprehensive Cancer Network